Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: A randomized controlled trial
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Excellent adherence to tuberculosis (TB) treatment is critical to cure TB and avoid the emergence of resistance. Wirelessly observed therapy (WOT) is a novel patient self-management system consisting of an edible ingestion sensor (IS), external wearable patch, and paired mobile device that can detect and digitally record medication ingestions. Our study determined the accuracy of ingestion detection in clinical and home settings using WOT and subsequently compared, in a randomized control trial (RCT), confirmed daily adherence to medication in persons using WOT or directly observed therapy (DOT) during TB treatment. METHODS AND FINDINGS: We evaluated WOT in persons with active Mycobacterium tuberculosis complex disease using IS-enabled combination isoniazid 150 mg/rifampin 300 mg (IS-Rifamate). Seventy-seven participants with drug-susceptible TB in the continuation phase of treatment, prescribed daily isoniazid 300 mg and rifampin 600 mg, used IS-Rifamate. The primary endpoints of the trial were determination of the positive detection accuracy (PDA) of WOT, defined as the percentage of ingestions detected by WOT administered under direct observation, and subsequently the proportion of prescribed doses confirmed by WOT compared to DOT. Initially participants received DOT and WOT simultaneously for 2-3 weeks to allow calculation of WOT PDA, and the 95% confidence interval (CI) was estimated using the bootstrap method with 10,000 samples. Sixty-one participants subsequently participated in an RCT to compare the proportion of prescribed doses confirmed by WOT and DOT. Participants were randomized 2:1 to receive WOT or maximal in-person DOT. In the WOT arm, if ingestions were not remotely confirmed, the participant was contacted within 24 hours by text or cell phone to provide support. The number of doses confirmed was collected, and nonparametric methods were used for group and individual comparisons to estimate the proportions of confirmed doses in each randomized arm with 95% CIs. Sensitivity analyses, not prespecified in the trial registration, were also performed, removing all nonworking (weekend and public holiday) and held-dose days. Participants, recruited from San Diego (SD) and Orange County (OC) Divisions of TB Control and Refugee Health, were 43.1 (range 18-80) years old, 57% male, 42% Asian, and 39% white with 49% Hispanic ethnicity. The PDA of WOT was 99.3% (CI 98.1; 100). Intent-to-treat (ITT) analysis within the RCT showed WOT confirmed 93% versus 63% DOT (p < 0.001) of daily doses prescribed. Secondary analysis removing all nonworking days (weekends and public holidays) and held doses from each arm showed WOT confirmed 95.6% versus 92.7% (p = 0.31); WOT was non-inferior to DOT (difference 2.8% CI [-1.8%, 9.1%]). One hundred percent of participants preferred using WOT. WOT associated adverse events were <10%, consisting of minor skin rash and pruritus associated with the patch. WOT provided longitudinal digital reporting in near real time, supporting patient self-management and allowing rapid remote identification of those who needed more support to maintain adherence. This study was conducted during the continuation phase of TB treatment, limiting its generalizability to the entire TB treatment course. CONCLUSIONS: In terms of accuracy, WOT was equivalent to DOT. WOT was superior to DOT in supporting confirmed daily adherence to TB medications during the continuation phase of TB treatment and was overwhelmingly preferred by participants. WOT should be tested in high-burden TB settings, where it may substantially support low- and middle-income country (LMIC) TB programs. TRIAL REGISTRATION: ClinicalTrials.gov NCT01960257.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bootstrap Methods and their Application
Davison, A. C., & Hinkley, D. V. (1997) · doi:10.1017/cbo9780511802843 · Cited by 7,350
Alipanah, N., Jarlsberg, L., Miller, C., Linh, N. N., Falzon, D., Jaramillo, E., & Nahid, P. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002595 · Cited by 503
Feasibility of an Ingestible Sensor-Based System for Monitoring Adherence to Tuberculosis Therapy
Belknap, R., Weis, S., Brookens, A., Au-Yeung, K. Y., Moon, G., DiCarlo, L., & Reves, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053373 · Cited by 160
Eisenberger, U., Wüthrich, R. P., Bock, A., Ambühl, P., Steiger, J., Intondi, A., Kuranoff, S., Maier, T., Green, D., DiCarlo, L., et al. (2013) · Transplantation · doi:10.1097/tp.0b013e31829b7571 · Cited by 85
Cited by
Cattamanchi, A., Crowder, R., Kityamuwesi, A., Kiwanuka, N., Lamunu, M., Namale, C., Tinka, L. K., Nakate, A. S., Ggita, J., Turimumahoro, P., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003628 · Cited by 83
Self-citationMedication management initiatives using wearable devices: scoping review
Iino, H., Kizaki, H., Imai, S., & Hori, S. (2024) · JMIR Human Factors · doi:10.2196/57652 · Cited by 12
Huda, M. H., Rahman, M. F., Zalaya, Y., Mukminin, M. A., Purnamasari, T., Hendarwan, H., Su’udi, A., Hasugian, A. R., Yuniar, Y., Handayani, R. S., et al. (2024) · PLOS ONE · doi:10.1371/journal.pone.0312001 · Cited by 8
Metadata
- Authors
- Browne, S. H., Umlauf, A., Tucker, A. J., Low, J., Moser, K., Gonzalez Garcia, J., Peloquin, C. A., Blaschke, T., Vaida, F., & Benson, C. A.
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2019-10-04
- Volume
- 16
- Issue
- 10
- Pages
- e1002891
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2978351943
- Cited by
- 87
- References
- 4
- FWCI
- 7.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: A randomized controlled trial. https://app.cochat.ai/papers/10.1371/journal.pmed.1002891
- The paper
- Browne, S. H., Umlauf, A., Tucker, A. J., Low, J., Moser, K., Gonzalez Garcia, J., Peloquin, C. A., Blaschke, T., Vaida, F., & Benson, C. A. (2019). Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: A randomized controlled trial. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1002891
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.